Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Wellferon, LelF A
Synonyms :
Interferon alpha-2, interferon alpha-A
Class :
Immunotherapy/antineoplastic/antiviral
Brand Name :
Wellferon, LelF A
Synonyms :
Interferon alpha-2, interferon alpha-A
Class :
Immunotherapy/antineoplastic/antiviral
Dosage Forms & Strengths
Injectable solutions
3MU/1ml
5MU/1ml
10MU/1ml
3MU subcutaneous or intramuscular, thrice daily for up to 48 weeks
Initial dose: 1.26- 6MU/sq.mt once a day subcutaneous or intramuscular for 1 to 4 weeks:
Maintenance dose: 2.5- 5MU/sq.mt thrice a week for upto six months
Dosage Forms & Strengths
Safety and efficacy study is not established
Refer to adult dosing
the risk of adverse effects may be increased
the risk of bleeding may be increased
the rate of metabolism of acenocoumarol may be reduced
the rate of metabolism of acetaminophen may be reduced
the risk of adverse effects may be increase
the risk of adverse effects may be increased
allogeneic processed thymus tissue
the therapeutic activity of allogenic processed thymus tissue may be reduced
the risk of adverse effects may be increased
the rate of metabolism of alosetron may be reduced
the risk of adverse effects may be increased
the rate of metabolism of aminophylline may be reduced
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of bleeding may be increased
the risk of bleeding may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of infection may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of thrombocytopenia and neutropenia may be increased
Actions and spectrum:
Type I interferon receptors like IFNAR1 and IFNAR2c are bound by interferon alpha, and these receptors activate and dimerize two Jak Janus kinases and tyrosine kinases namely Jak1 and Tyk2. These phosphorylate receptors and transphosphorylate themselves.
Following their binding to Stat1 and 2, which are transcription activators and signal transducers, the phosphorylated INFAR receptors activate and dimerize many (about 100)antiviral and immunomodulatory proteins. Compared to interferon beta, interferon alpha binds to interferon receptors of type I less stably.
Frequency not defined
Hypotension
Edema
Alopecia
Dry skin
Depression
Chills
Insomnia
Irritability
Headache
Hypocalcemia
Suppression of bone marrow
Hemolytic anemia
Visual disturbances
Pulmonary congestion
Proteinuria
Hearing changes
Bloating
Sexual dysfunction
Throat irritation
Irregular menstruation
Angioedema
Acute renal failure
Ischaemic attack
Black Box Warning
Never operate machinery or drive a vehicle
Contraindication/Caution:
Contraindication:
Hypersensitivity
Chronic hepatitis
Epilepsy
Renal impairment
Myocardial infarction
Arrhythmia
Thyroid disorder
Pregnancy consideration:
USFDA pregnancy category: C
Lactation:
The data about the excretion of interferon alfa-n1 into breast milk is not known.
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Pharmacodynamics:
It increases the effectiveness of peptides derived from viral antigens by upregulating the expression of MHC I proteins. This improves the macrophage’s suitability for CTL-mediated killing by boosting the activation of CD8+ T cells, which are the progenitors of cytotoxic T lymphocytes (CTLs). In addition, interferon alpha stimulates the production of multiple essential antiviral mediators, such as protein kinase R and 2′-5′ oligoadenylate synthetase (2′-5′ A synthetase).
Pharmacokinetics:
limited ADME data is available
Absorption
80% of the drug administered intramuscularly or subcutaneously is absorbed. The time to obtain peak serum concentration is 15min to 60 minutes
Half-life:
1.2 hours, as noticed in an invitro study with mammalian reticulocytes
Administration:
To be administered as advised by the physician
Patient information leaflet
Generic Name: interferon alfa- n1
Why do we use interferon alfa- n1?
A purified form of human interferon called interferon alfa-n1 is used to treat genital warts caused by the human papillomavirus by promoting the innate antiviral response.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
